NRXPW
NRx Pharmaceuticals, Inc.
Set alert
- YTD
- -61.10%
- 1 year
- -61.10%
- Open
- 0.0142
- Prev close
- 0.0142
- Mkt cap
- 361.78K
- Vol
- 0
- Avg vol
- 0
- EPS
- -6.25
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0142
- High
- 0.0142
- Forward P/E
- 0.00
- Beta
- 1.27
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -6.25
- Beta
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -7.35M
- Total cash
- 1.90M
- Total debt
- 7.65M
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nrxpharma.com
News
Your note
Sign in to keep a note on NRXPW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Truist Financial Corp | 1.09% | 38,965 | 2.73K | Sep 29, 2024 |
| Virtu Financial LLC | 0.97% | 34,688 | 2.43K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.49% | 17,400 | 1.22K | Sep 29, 2024 |
| Wolverine Asset Management, LLC | 0.43% | 15,392 | 1.08K | Sep 29, 2024 |
| UBS Group AG | 0.43% | 15,251 | 1.07K | Sep 29, 2024 |
| Johnson Financial Group, Inc. | 0.01% | 315 | 22 | Sep 29, 2024 |